Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Daniella Klebaner, Emory Univ, Emory University, Rollins Sch Publ Hlth, Dept Epidemiol
  • ,
  • Stephen Hamilton-Dutoit
  • Thomas Ahern, Univ Vermont, University of Vermont, Robert Larner MD Coll Med, Dept Surg, Univ Vermont, University of Vermont, Dept Biochem, Robert Larner MD Coll Med
  • ,
  • Anatasha Crawford, Emory Univ, Emory University, Rollins Sch Publ Hlth, Dept Epidemiol
  • ,
  • Thomas Jakobsen
  • Deirdre P. Cronin-Fenton
  • Per Damkier, Odense Univ Hosp, Odense University Hospital, Dept Clin Chem & Pharmacol
  • ,
  • Emiel Janssen, Stavanger Univ Hosp, Dept Pathol
  • ,
  • Anders Kjaersgaard
  • Anne Gulbech Ording
  • ,
  • Havard Soiland, Univ Bergen, University of Bergen, Dept Clin Sci
  • ,
  • Henrik Toft Sorensen
  • Timothy L. Lash
  • Ylva Hellberg, Aarhus Univ Hosp, Aarhus University, Inst Pathol

Background Apolipoprotein D (ApoD) has been proposed as a predictor of breast cancer recurrence among estrogen receptor-positive (ER+), tamoxifen-treated patients.

Methods We conducted a population-based case-control study nested in a population of 11,251 women aged 35-69 years at diagnosis with Stage I-III breast cancer between 1985 and 2001 on Denmark's Jutland Peninsula and registered with the Danish Breast Cancer Coop-erative Group. We identified 541 recurrent or contralateral breast cancers cases among women with ER+ disease treated with tamoxifen for at least 1 year and 300 cases in women with ER-disease never treated with tamoxifen. We matched one control subject per case and assessed ApoD expression in the tumor cell nucleus and cytoplasm using tissue micro-array immunohistochemistry. We computed the odds ratio (OR) associating ApoD expression with recurrence and adjusted for potential confounding using logistic regression.

Results Cytoplasmic ApoD expression was seen in 68% of ER+ tumors, in 66% of ER-tumors, and in 66% of controls across both groups. In women with ER+ tumors, the associations of cyto-plasmic ApoD expression with recurrence (OR = 1.0; 95% CI = 0.7 to 1.4) and increasing cytoplasmic expression with recurrence (OR = 1.0; 95% CI = 0.996 to 1.003) were null, as were those for women with ER-tumors. Associations for nuclear ApoD expression and combined nuclear and cytoplasmic expression were similarly near-null.

Conclusion ApoD expression is likely not a predictor of recurrence in tamoxifen-treated patients.

Original languageEnglish
Article number0171253
JournalP L o S One
Volume12
Issue3
Number of pages12
ISSN1932-6203
DOIs
Publication statusPublished - 16 Mar 2017

    Research areas

  • ADJUVANT ENDOCRINE THERAPY, BINDING CYST PROTEIN, ESTROGEN-RECEPTOR, MECHANISMS, RESISTANCE, REGISTRATION, SURVIVAL, DENMARK, MARKERS, TRENDS

See relations at Aarhus University Citationformats

ID: 121760520